DNTH
Dianthus Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.90B
P/E Ratio
—
EPS
$-4.20
Beta
0.21
52W High
$92.27
52W Low
$16.64
50-Day MA
$67.66
200-Day MA
$42.02
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $2.04M |
| Gross Profit (TTM) | $2.04M |
| EBITDA | $-177.82M |
| Operating Margin | -24486.00% |
| Return on Equity | -38.40% |
| Return on Assets | -24.60% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $11.41 |
| Price-to-Book | 9.91 |
| Price-to-Sales (TTM) | 2406.87 |
| EV/Revenue | 2202.83 |
| EV/EBITDA | -7.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -78.60% |
| Shares Outstanding | $54.45M |
| Float | $41.91M |
| % Insiders | 0.13% |
| % Institutions | 95.56% |
Historical Volatility
HV 10-Day
39.73%
HV 20-Day
34.49%
HV 30-Day
78.34%
HV 60-Day
72.52%
HV Rank
75.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($125.46 target)
15
BuyData last updated: 4/14/2026